Adherent methods for lentiviral vector (LVV) production are widely used as these processes are easily available, require minimal investment to implement, and have been successfully utilized for commercially approved gene therapy products. However, adherent methods have shown their limitations due to lack of scalability, high variability, challenges with consistently meeting safety and efficacy requirements and due to unsustainable costs for commercialization. Lonza's suspension transient transfection platform for LVV addresses these challenges, offering a secure path to commercialization for customers to scale their production while maintaining high product quality and consistent supply. Join this webinar to learn more about Lonza’s LVV suspension platform and secure commercial viability for your gene therapies.